APPLICATION OF VASOSTENON FOR TREATING PATIENTS WITH SEVERE CHRONIC ISCHEMIA IN OCCLUSIVE PERIPHERAL ARTERIAL DISEASE OF LOWER LIMBS
Objective. To determine the efficacy and safety of Vasostenon in patients with severe chronic obliterating diseases of the lower limb arteries, stages III and IV (according to pontaine's classification). Materials and methods. An open multicenter non-comparative uncontrolled prospective non-interventional study was carried out to assess the Vasostenon efficacy and safety in patients with severe chronic obliterating diseases of peripheral arteries. Results. Based on the inclusion and exclusion criteria 15 men (60%) and 10 women took part in the study, the mean age was 66.04 ± 10.11 years. A statistically significant decrease in the level of day and night pain according to a visual analog scale was revealed 10 days after the therapy start compared to the baseline level. The average value of daytime pains decreased to 15.38 (p<0.01), the average value of nighttime pains decreased to 15.50 (p <0.01). After the treatment course, the daily consumption of analgesics decreased reliably in 23 (92.0%) patients, 2 (8.0%) patients retained the analgesic initial dosage. Conclusion.Vasostenon is effective and safe in reducing the level of pain in patients with severe chronic obliterating diseases of the lower limb arteries and helps to reduce the number of analgesics used.